PCSA Processa Pharmaceuticals Inc

  1. Stocks
  2. Healthcare
  3. NASDAQ: PCSA

Price (delayed)

$2.17

Market cap

$6.2M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$8.48

Enterprise value

$1.64M

Processa Pharmaceuticals, Inc. was founded in 2017 in Hanover, Maryland, with a mission to develop products that can improve the survival and/or quality of life for patients who have a ...

Highlights
The EPS has soared by 75% YoY and by 64% from the previous quarter
PCSA's net income has soared by 59% YoY and by 49% QoQ
Processa Pharmaceuticals's equity has decreased by 33% YoY and by 30% QoQ
Processa Pharmaceuticals's quick ratio has decreased by 23% QoQ
Sector: Healthcare
Industry: Biotechnology
Website: http://processapharmaceuticals.com
Peers: OPTN OPK ORGO

Key stats

What are the main financial stats of PCSA
Market
Shares outstanding
2.86M
Market cap
$6.2M
Enterprise value
$1.64M
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
0.54
Price to sales (P/S)
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
Earnings
Revenue
$0
EBIT
-$11.12M
EBITDA
-$11.04M
Free cash flow
-$8.07M
Per share
EPS
-$8.48
Free cash flow per share
-$6.15
Book value per share
$4.05
Revenue per share
$0
TBVPS
$4.41
Balance sheet
Total assets
$5.79M
Total liabilities
$797,484
Debt
$150,554
Equity
$4.99M
Working capital
$4.9M
Liquidity
Debt to equity
0.03
Current ratio
7.71
Quick ratio
6.44
Net debt/EBITDA
0.41
Margins
EBITDA margin
N/A
Gross margin
N/A
Net margin
N/A
Operating margin
N/A
Efficiency
Return on assets
-122.2%
Return on equity
-141.4%
Return on invested capital
-2,795.1%
Return on capital employed
-220%
Return on sales
N/A
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

PCSA stock price

How has the Processa Pharmaceuticals stock price performed over time
Intraday
-3.98%
1 week
0.93%
1 month
-8.05%
1 year
-83.56%
YTD
-67.57%
QTD
-8.25%

Financial performance

How have Processa Pharmaceuticals's revenue and profit performed over time
Revenue
$0
Gross profit
$0
Operating income
-$11.46M
Net income
-$11.12M
Gross margin
N/A
Net margin
N/A
PCSA's net income has soared by 59% YoY and by 49% QoQ
Processa Pharmaceuticals's operating income has surged by 58% YoY and by 48% QoQ

Growth

What is Processa Pharmaceuticals's growth rate over time

Valuation

What is Processa Pharmaceuticals stock price valuation
P/E
N/A
P/B
0.54
P/S
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
The EPS has soared by 75% YoY and by 64% from the previous quarter
PCSA's P/B is 89% below its 5-year quarterly average of 5.1 and 58% below its last 4 quarters average of 1.3
Processa Pharmaceuticals's equity has decreased by 33% YoY and by 30% QoQ

Efficiency

How efficient is Processa Pharmaceuticals business performance
Processa Pharmaceuticals's return on equity has increased by 45% QoQ and by 12% YoY
The ROA has grown by 45% from the previous quarter and by 18% YoY
Processa Pharmaceuticals's return on invested capital has increased by 22% QoQ

Dividends

What is PCSA's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for PCSA.

Financial health

How did Processa Pharmaceuticals financials performed over time
Processa Pharmaceuticals's total assets has decreased by 33% YoY and by 28% QoQ
PCSA's total liabilities is down by 31% year-on-year and by 13% since the previous quarter
PCSA's debt is 97% smaller than its equity
Processa Pharmaceuticals's debt to equity has soared by 50% from the previous quarter
PCSA's debt is down by 34% year-on-year and by 12% since the previous quarter

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.